If this trial is representative of R327's usefulness, an expansion to other test sites ought to lead to comparable results that would indicate excellent efficacy for R327. In a market that sees a cost to even the US healthcare system alone of US$9-13B per year, can you imagine what a new drug that 'cures' DFI like these within a couple of weeks of topical treatment is going to be worth to the company in revenues?
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion, page-7
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
-0.015(2.86%) |
Mkt cap ! $121.5M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 52.0¢ | 51.0¢ | $13.94K | 27.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 8829 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 27041 | 2 |
View Market Depth
| Last trade - 10.52am 13/09/2024 (20 minute delay) ? |
| RCE (ASX) Chart |